Medical Information

The usage and dosage of Lusatrombopag should be adjusted according to the indications and individual patient conditions. Special attention should be paid to liver function and thrombus risk when using it for special populations. The following provides a detailed explanation of common usage, dosage adjustment, and precautions for special populations.

1. Conventional usage and dosage

(1) Chronic liver disease associated thrombocytopenia: The recommended dosage is 3mg orally per day, taken continuously for 7 days. Medication should be administered 8-14 days prior to the planned invasive procedure.

(2) Medication method: It should be taken together with food to improve bioavailability, and it is recommended to fix the daily medication time. Tablets should be swallowed whole and should not be broken or chewed.

2. Principle of dose adjustment

(1) Platelet monitoring: During treatment, platelet count should be checked weekly. If it exceeds 200 × 10 ⁹/L, medication should be suspended. The platelet peak usually occurs 7-14 days after the last administration.

(2) Liver function adjustment: Child Pugh C patients should reduce their dosage to 1.5mg per day and closely monitor platelet and liver function indicators.

3. Medication for special populations

(1) Pregnant women

Animal experiments have shown embryonic toxicity, and human data is limited. Use only when the potential benefits outweigh the risks, and strict contraception is required during treatment.

(2) Lactating women

Medication may be secreted into breast milk. It is recommended to suspend breastfeeding during the treatment period and for 28 days after discontinuation of medication.

(3) Child patients

The safety and efficacy of using it for patients under 18 years old have not been established and is not recommended.

(4) Elderly patients

Patients over 65 years old do not need to adjust their dosage, but they need to strengthen thrombus monitoring, especially for those with concomitant cardiovascular disease.

(5) Liver dysfunction

Child Pugh A/B patients do not require adjustment; Child Pugh C patients need to reduce their dosage by 50% and extend the platelet monitoring period.

(6) Renal insufficiency

Mild to moderate renal dysfunction does not require dose adjustment. Insufficient data on patients with end-stage renal disease, it is recommended to use with caution.